Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Piperacillin-tazobactam vs Cefoxitin for prophylaxis in pancreatoduodenectomy
NCT03269994Phase 3Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Nov 2017
- Primary completion
- Jan 2025
- Modality
- Irreversible Covalent Inhibitors
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of piperacillin + tazobactam in surgical site infection (SSI), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Surgical Site Infection at 30 days. Started Nov 2017; status: completed.
02
Drugs
piperacillin + tazobactam
03
Conditions
surgical site infection (SSI)
Beyond the preview
Go deeper on NCT03269994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03269994.